grants_govRFA-DA-26-034
Open
Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
- Response deadline
- Nov 18, 2027 Due in 397 days
- Date posted
- Nov 20, 2024
- Source
- Open notice
Description
This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.
Classifications
- NAICS93.839
Documents (1)
- DownloadRFA-DA-26-034-Full-Announcement.htmltext/html429 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)Due Oct 9, 2028
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)Due Jan 7, 2027
- NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)Due Jan 7, 2028
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)Due Jan 7, 2028
- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)Due Dec 23, 2027
- Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)Due Dec 23, 2027